Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Teva Pharmaceutical Industries Ltd (TEVA)

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,702,472
  • Shares Outstanding, K 1,092,089
  • Annual Sales, $ 18,854 M
  • Annual Income, $ -2,150,000 K
  • 60-Month Beta 1.83
  • Price/Sales 0.55
  • Price/Cash Flow 2.07
  • Price/Book 0.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.59
  • Number of Estimates 6
  • High Estimate 0.64
  • Low Estimate 0.54
  • Prior Year 0.55
  • Growth Rate Est. (year over year) +7.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.32 +4.81%
on 11/14/19
10.99 -11.10%
on 11/25/19
-0.01 (-0.10%)
since 11/13/19
3-Month
6.44 +51.71%
on 10/09/19
10.99 -11.10%
on 11/25/19
+1.83 (+23.05%)
since 09/13/19
52-Week
6.07 +60.96%
on 08/15/19
20.21 -51.66%
on 02/05/19
-9.25 (-48.63%)
since 12/13/18

Most Recent Stories

More News
Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

NVS : 92.93 (-0.14%)
AXSM : 47.40 (-2.41%)
JAZZ : 148.05 (-1.23%)
TEVA : 9.70 (-1.02%)
J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

JNJ : 140.59 (-0.53%)
ENDP : 4.68 (-0.43%)
TEVA : 9.70 (-1.02%)
MNK : 3.62 (-1.90%)
Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

RHHBY : 38.2650 (-0.46%)
PFE : 38.13 (-1.06%)
TEVA : 9.70 (-1.02%)
MYL : 19.27 (-2.08%)
Acne Drugs Market Growth Opportunities on Sales, Technological Advancements and Revenue Overview 2019-2028

AGN : 188.41 (+0.07%)
GSK : 45.99 (+0.13%)
MAYNF : 0.3023 (+7.96%)
TEVA : 9.70 (-1.02%)
VRX.TO : 30.80 (-3.33%)
Thinking about buying stock in Apple, General Electric, Macy's, Nio, or Teva Pharmaceutical?

InvestorsObserver issues critical PriceWatch Alerts for AAPL, GE, M, NIO, and TEVA.

AAPL : 272.84 (+0.51%)
GE : 11.35 (-0.79%)
M : 15.29 (-2.67%)
NIO : 2.38 (+4.85%)
TEVA : 9.70 (-1.02%)
Fed Reportedly Opens Criminal Investigation on Opioid Makers

Shares of some manufacturers and distributors of opioid drugs decline on Tuesday following reports that a criminal probe has been initiated by federal prosecutors.

JNJ : 140.59 (-0.53%)
ENDP : 4.68 (-0.43%)
MNK : 3.62 (-1.90%)
TEVA : 9.70 (-1.02%)
MCK : 141.73 (-1.53%)
ABC : 85.69 (-1.27%)
AMRX : 4.70 (-6.75%)
Teva Announces Early Tender Results of its Debt Tender Offer and Election of Early Settlement

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today the early tender results in connection with its previously announced tender offers (the "Offers") to purchase for cash...

TEVA : 9.70 (-1.02%)
Endo's (ENDP) BLA for Cellulite Treatment Accepted by FDA

The FDA accepts Endo's (ENDP) BLA for CCH for the treatment of cellulite in the buttocks.

ENDP : 4.68 (-0.43%)
JAZZ : 148.05 (-1.23%)
MNK : 3.62 (-1.90%)
TEVA : 9.70 (-1.02%)
Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes

Teva Pharmaceutical Industries Limited (NYSE and TASE: TEVA) ("Teva") announced today that it successfully upsized and priced approximately $2.1 billion (equivalent) of its senior notes (the "Notes")....

TEVA : 9.70 (-1.02%)
Why Oncology Drugs are Projected to Generate the Largest Pharma Revenues

A lot of cancer research is dealing with shrinking brain tumors and opening the door for targeted cancer therapies to work without damaging the surrounding tissue. The success rate for cancer therapies...

CNSP : 3.93 (-2.48%)
AMRN : 23.76 (+3.35%)
TEVA : 9.70 (-1.02%)
KRTX : 68.32 (-7.06%)
ACST : 1.86 (+6.29%)
ACST.VN : 2.440 (+5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade TEVA with:

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 10.11
1st Resistance Point 9.96
Last Price 9.70
1st Support Level 9.59
2nd Support Level 9.38

See More

52-Week High 20.21
Fibonacci 61.8% 14.81
Fibonacci 50% 13.14
Fibonacci 38.2% 11.47
Last Price 9.70
52-Week Low 6.07

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar